139 related articles for article (PubMed ID: 7736536)
1. Combined use of 111In-labeled pentetreotide and three-step immunoscintigraphy with antichromogranin A monoclonal antibody in the diagnosis of pituitary adenomas.
Magnani P; Paganelli G; Siccardi AG; Songini C; Colombo P; Faglia G; Fazio F
Cell Biophys; 1994; 24-25():307-13. PubMed ID: 7736536
[TBL] [Abstract][Full Text] [Related]
2. Three-step immunoscintigraphy with anti-chromogranin A monoclonal antibody in tumours of the pituitary region.
Colombo P; Siccardi AG; Paganelli G; Magnani P; Songini C; Buffa R; Faglia G; Fazio F
Eur J Endocrinol; 1996 Aug; 135(2):216-21. PubMed ID: 8810736
[TBL] [Abstract][Full Text] [Related]
3. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
4. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
[TBL] [Abstract][Full Text] [Related]
5. In vivo imaging of chromogranin A-positive endocrine tumours by three-step monoclonal antibody targeting.
Siccardi AG; Paganelli G; Pontiroli AE; Pelagi M; Magnani P; Viale G; Faglia G; Fazio F
Eur J Nucl Med; 1996 Nov; 23(11):1455-9. PubMed ID: 8854841
[TBL] [Abstract][Full Text] [Related]
6. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
[TBL] [Abstract][Full Text] [Related]
7. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
[TBL] [Abstract][Full Text] [Related]
8. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
[TBL] [Abstract][Full Text] [Related]
9. 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy.
Yüksel M; Eziddin S; Wardelmann E; Biersack HJ
Rev Esp Med Nucl; 2006 Sep; 25(5):316-9. PubMed ID: 17173778
[TBL] [Abstract][Full Text] [Related]
10. Pretargeted immunoscintigraphy in patients with medullary thyroid carcinoma.
Magnani P; Paganelli G; Songini C; Samuel A; Sudati F; Siccardi AG; Fazio F
Br J Cancer; 1996 Sep; 74(5):825-31. PubMed ID: 8795589
[TBL] [Abstract][Full Text] [Related]
11. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
12. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
13. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
14. Imaging of bronchial carcinoid tumors associated to Cushing syndrome with 111In-Octreoscan scintigraphy and immunoscintigraphy with anti-chromogranin monoclonal antibodies. Report of two cases.
Carretta A; Chiesa G; Magnani P; Songini C; Melloni G; Zannini P; Grossi A
J Cardiovasc Surg (Torino); 1997 Apr; 38(2):191-4. PubMed ID: 9201136
[TBL] [Abstract][Full Text] [Related]
15. Immunoscintigraphy with anti-chromogranin A antibodies in patients with endocrine/neuroendocrine tumors.
Colombo P; Paganelli G; Magnani P; Songini C; Fazio F; Faglia G
J Endocrinol Invest; 1993 Nov; 16(10):841-3. PubMed ID: 8144860
[No Abstract] [Full Text] [Related]
16. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
18. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
[TBL] [Abstract][Full Text] [Related]
19. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
[TBL] [Abstract][Full Text] [Related]
20. Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas.
Lastoria S; Colao A; Vergara E; Ferone D; Varrella P; Merola B; Lombardi G; Salvatore M
Eur J Endocrinol; 1995 Jul; 133(1):38-47. PubMed ID: 7627336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
